Zydus Lifesciences Share Price in Focus After subsidiary Licenses Progerinin for Hutchinson-Gilford Progeria Syndrome

Sentynl Therapeutics, a subsidiary of Zydus Lifesciences Limited, has entered into an agreement with PRG S&T to license Progerinin, an investigational drug for Hutchinson-Gilford Progeria Syndrome (HGPS). This move strengthens Sentynl's portfolio in rare diseases. 

Progerinin Acquisition Details 

Sentynl Therapeutics has acquired full rights to Progerinin (SLC-D011), a drug candidate for HGPS, from PRG S&T.  

This agreement allows Sentynl to advance the clinical development of Progerinin, which has orphan drug status from the US FDA. The drug is in the final stages of a Phase 2A clinical trial, with data expected by mid-2026. 

Significance of Progerinin in HGPS Treatment 

Progerinin is an orally active small-molecule drug aimed at treating HGPS, a rare genetic disorder causing accelerated aging in children.  

It targets progerin, an abnormal protein resulting from an LMNA gene mutation. By inhibiting progerin's harmful effects, Progerinin aims to improve nuclear integrity and reduce cellular damage. 

Current Treatment Landscape for HGPS 

Currently, Zokinvy (lonafarnib) is the only approved treatment for HGPS and certain progeroid laminopathies in several countries, including the US and EU. Progerinin offers a potential new therapeutic option, with early research showing promising results in mouse models. 

Read More: Ramky Infrastructure Subsidiary Signs Concession Agreement for Pharma Park in Maharashtra! 

About the Collaborating Companies 

Zydus Lifesciences Limited is a leading life-sciences company with a global presence. Sentynl Therapeutics, its US-based subsidiary, focuses on innovative therapies for rare diseases. PRG S&T is a Korean R&D company specialising in treatments for rare genetic diseases. 

Zydus Lifesciences Share Price Performance 

As of March 17, 2026, at 9:30 AM, Zydus Lifesciences share price on NSE was trading at ₹895.35 up by 0.95% from the previous closing price. 

Conclusion 

The licensing of Progerinin by Sentynl Therapeutics marks a significant step in the development of treatments for Hutchinson-Gilford Progeria Syndrome. This collaboration with PRG S&T aims to bring new hope to patients affected by this rare genetic disorder. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.